The Role of the Qualified Person in European Pharmaceutical Regulations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Role of the Qualified Person in European Pharmaceutical Regulations
The authors provide a brief overview of the European pharmaceutical regulation with regard to batch certification by a qualified person and batch release for the European market.


Pharmaceutical Technology
Volume 10, Issue 34

References

1. FDA, "Pharmaceutical cGMPs for the 21st Century—A Risk-Based Approach," Final Report, (Rockville, MD, September 2004).

2. Code of Federal Regulations, Title 21, Food and Drugs, (Government Printing Office, Washington, DC), Part 210 and Part 211.

3. European Commission, EudraLex, Volume 4: EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use (Brussels, Feb. 2008).

4. European Commission, Commission Directive 2001/83/EC, "Community Code Relating to Medicinal Products for Human Use," (Brussels, Dec. 2008).

5. European Commission, Commission Directive 2001/82/EC, "Community Code Relating to Veterinary Medicinal Products," (Brussels, Nov. 2004).

6. European Commission, Commission Directive 2001/20/EC, "The Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use," (Brussels, May 2001).

7. European Commission, Commission Directive 2005/28/EC, "Laying Down Principles and Detailed Guidelines for Good Clinical Practice as Regards Investigational Medicinal Products for Human Use, as well as the Requirements for Authorisation of the Manufacturing or Importation of Such Products," (Brussels, Apr. 2005).

8. European Commission, Annex 16 to the EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use: "Certification by a Qualified person and Batch Release," (Brussels, July 2001).

9. European Medicines Agency, Reflection Paper on a Proposed Solution for Dealing with Minor Deviations from the Detail Described in the Marketing Authorisation for Human and Veterinary Medicinal Products, Rev1, (London, Jan. 2009).

10. European Commission, Council Directive 75/318/EEC, "The Approximation of the Laws of Member States Relating to Analytical, Pharmaco-Toxicological and Clinical Standards and Protocols in Respect of the Testing of Proprietary Medicinal Products," (Brussels, May 1975).

11. Qualified Person Association, "Good Practice Guide No 2: Duties and Responsibilities for Qualified Persons in the EU," (Heidelberg, Germany, 2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
44%
Facility/environment problems
0%
Process development problems
11%
Production equipment downtime
11%
Raw material supply problems
11%
Regulatory restrictions
0%
Business decisions to limit production
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: Pharmaceutical Technology,
Click here